106 -2 (40) 2022 — Abdurakhmanov M.M., Eshonov O.Sh., — COVID-19 AND LIVER DAMAGE

COVID-19 AND LIVER DAMAGE

Abdurakhmanov M.M., Bukhara State Medical Institute

Eshonov O.Sh., Bukhara State Medical Institute

Abdurakhmanov Z.M. Bukhara State Medical Institute

Tagaeva X.D., Bukhara State Medical Institute

Kayumov M.T. Bukhara State Medical Institute

Resume

Currently, COVID-19 is considered as a systemic disease with impaired immune system function, affecting primarily the lungs, but also the heart, kidneys, intestines, liver and spleen. Liver damage occurs mainly in severe COVID-19. Potential mechanisms of liver damage caused by SARS-CoV-2 have been described, expanding our knowledge of COVID-19.

Keywords: COVID-19, liver damage.

First page

539

Last page

536

For citation: Abdurakhmanov M.M., Eshonov O.Sh., Abdurakhmanov Z.M., Tagaeva X.D., Kayumov M.T. COVID-19 AND LIVER DAMAGE //New Day in Medicine 2(40)2022 539-536 https://clck.ru/ebq2c

LIST OF REFERENCES:

  1. Cuker A., Peyvandi F. Coronavirus disease 2019 (COVID-19): Hypercoagulability. Literature review, 2020.
  2. Connors J.M., Levy J.H. Thromboinflammation and the hypercoagulability of COVID-19 // J. Thromb. Haemost. 2020 // www.hematology.org/covid-19/covid-19-and-coagulopathy.
  3. Oblokulov, A.R., Niyozov, G.E. Clinical and epidemiological characteristics of patients with COVID-19 (2020) //International Journal of Pharmaceutical Research, 12 (4), pp. 3749-3752.
  4. Zhang C., Shi L., Wang F.-S. Liver injury in COVID-19: management and challenges // Lancet Gastroenterol. Hepatol. 2020. Vol. 5. № 5. P. 428–430.
  5. Zippi M., Fiorino S., Occhigrossi G., Hong W. Hypertransaminasemia in the course of infection with SARS-CoV-2: incidence and pathogenetic hypothesis // World J. Clin. Cases. 2020. Vol. 8. № 8. P. 1385–1390.
  6. Chai X., Hu L., Zhang Y. et­al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection // bioRxiv. 2020.
  7. Li J., Fan J.G. Characteristics and mechanism of liver injury in 2019 coronavirus disease // J. Clin. Transl. Hepatol. 2020. Vol. 8. № 1. P. 13.
  8. Mehta P., McAuley D.F., Brown M.­et al. COVID-19: consider cytokine storm syndromes and immunosuppression // Lancet. 2020. Vol. 395. № 10229. P. 1033–1034.
  9. Huang C., Wang Y., Li X. et­al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China // Lancet. 2020. Vol. 395. № 10223. P. 497–506.
  10. Boettler T., Newsome P.N., Mondelli M.U. et­al. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper // JHEP Reports. 2020.
  11. Bioquard L., Valla D., Rautou P.-E. No evidence for an increased liver uptake of SARS-CoV-2 in metabolic associated fatty liver disease // J. Hepatol. 2020.

file

download